-

Known Medicine Announces BioTech Breakthrough Award for “Best Use of Artificial Intelligence in BioTech 2022”

Known Medicine was selected out of a pool of 1,350 nominations worldwide.

SALT LAKE CITY--(BUSINESS WIRE)--Known Medicine, a rising biotechnology company, has been awarded the prestigious “Best Use of Artificial Intelligence in BioTech 2022” by BioTech Breakthrough Awards.

Known Medicine is building the world’s largest purpose-built 3-dimensional (3D) cell culture dataset with millions of images of patient cancer cells responding to hundreds of drugs and combinations. Their machine learning-based analysis relies on high-content images of these 3D micro-tumors to better understand why cells respond to one treatment over another. Functional outcomes are combined with high dimensional -omics datasets to identify the best patients for existing drugs, and the best new drug candidates. Their ability to capture patient-to-patient variability allows us to narrow the drug discovery funnel to identify a best-in-class molecule. Additionally, they were recently recognized by VentureBeat, who named Known Medicine as the recipient of their AI Innovators award. This award spotlights a startup that holds great promise for making an impact with its AI innovation.

About BioTech Breakthrough Awards

The BioTech Breakthrough Awards program aims to perform the most comprehensive evaluation of life sciences and biotechnology tools, services and companies today, with nominations coming in from the best and brightest biotechnology innovators around the world. All award nominations are fully analyzed, evaluated and scored by our expert panel of judges, representing a mix of technical, business, academic and marketing expertise within the industry. The evaluation criteria for the BioTech Breakthrough Awards program are focused around the concept of innovation. We have developed the evaluation criteria and a corresponding set of assessment tools and scales that we believe allow for a fair, honest and equitable assessment of each entry. https://biotechbreakthroughawards.com/award-winners/

About Known Medicine

Based in Salt Lake City, UT, Known Medicine is building a predictive engine that captures patient-to-patient variability to develop the best drug for every cancer. Known Medicine merges cancer biology and machine learning to understand drug efficacy and patient-specific predictors of response. By understanding how and why a patient responds to which therapy, Known Medicine is able to develop effective drug treatments with a high likelihood of success, and discover new drugs as its engine grows. Learn more at www.knownmed.com, or connect on Twitter and LinkedIn.

Contacts

Andrea Mazzocchi PhD, Co-founder & CEO
andrea@knownmed.com
801-953-0895

Known Medicine


Release Versions

Contacts

Andrea Mazzocchi PhD, Co-founder & CEO
andrea@knownmed.com
801-953-0895

Social Media Profiles
More News From Known Medicine

Pathos AI Completes Acquisition of Rain Oncology

CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”) for $1.16 per share in cash plus one contingent value right per share (each, a “CVR”), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions...

Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor

CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline. FT-7051 was developed by Forma Therapeutics, which was acquired by Novo Nord...

Known Medicine Appoints Kristen Fortney to Advisory Board

SALT LAKE CITY & RICHMOND, Calif.--(BUSINESS WIRE)--Known Medicine is pleased to announce it has appointed Kristen Fortney, PhD, as an advisor. Dr. Fortney is the CEO and co-founder of BioAge Labs, a clinical stage drug discovery company in Richmond, CA. BioAge utilizes longitudinal patient data and artificial intelligence (AI) to identify the causes of age-related diseases. “Dr. Fortney brings her personal experience as the CEO of a clinical stage, platform-based drug discovery company to our...
Back to Newsroom